SCHEMBL26645565

SCHEMBL26645565

CC(C)(C)OC(=O)N1CCn2nc(Nc3ccc(Cl)cc3F)cc2C1.[Ar]

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 2/20 0.54
▸ USP30 Q70CQ3 1/20 0.48
▸ CYP3A4 P08684 3/20 0.45
▸ CYP3A5 P20815 2/20 0.45
▸ GPR119 Q8TDV5 2/20 0.42
▸ NR1H2 P55055 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ STS P08842 1/20 0.39
▸ BTK Q06187 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TRPC3 Q13507 1/20 0.38
▸ TRPC6 Q9Y210 1/20 0.38
▸ ALK Q9UM73 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26645284 0.99 MKNK1 (0.55) MKNK1USP30CYP3A4CYP3A5GPR119
SCHEMBL26645717 0.81 MKNK1 (0.55) MKNK1USP30CYP3A4CYP3A5GPR119
SCHEMBL26645720 0.81 NR1H2 (0.44) MKNK1NR1H2KMT2AMEN1
SCHEMBL26645345 0.80 CYP3A4 (0.48) MKNK1USP30CYP3A4CYP3A5GPR119
SCHEMBL30623068 0.79 GALR2 (0.53) MKNK1NR1H2STSALDH1A1ALK
SCHEMBL26645091 0.79 GALR2 (0.53) MKNK1NR1H2STSALDH1A1ALK
SCHEMBL26645516 0.79 NR1H2 (0.46) GPR119NR1H2POLB
SCHEMBL26645173 0.78 MAPT (0.52) GPR119NR1H2KMT2AMEN1STS
SCHEMBL30622856 0.78 GALR2 (0.54) MKNK1NR1H2STSALDH1A1ALK
SCHEMBL26645437 0.78 GALR2 (0.54) MKNK1NR1H2STSALDH1A1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519265-A1 IRREVERSIBLE MUTEGFR INHIBITORS Bayer Aktiengesellschaft (DE) 2025-03-12 — — EP disclosed
WO-2023213882-A1 IRREVERSIBLE MUTEGFR INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-09 — — WO disclosed
Send feedback